To those who have joined our team as investors - and we are proud to say there are over 500 of us - we extend our most sincere thanks.  We are working diligently to live up to the expectations we all have in our technology playing a key role in providing a meaningful therapy and cure for HIV through the use of monoclonal antibodies.  

For those who have not yet invested or who have not given us a close look, we ask that you do so now.  Even a small investment can play a meaningful role while also being a sound investment.  

A prospective investor wrote yesterday asking me to describe the financial potential of our technology addressing the HIV pandemic and the justification for our valuation CAP of $10 Million.  Given the severity of the pandemic - 37 million people infected and 2.1 million new cases each year - the seriousness of this health condition and the need for a real therapy cannot be overstated.  Using very conservative assumptions, Navigant Consulting calculated that a successful treatment - treating only those in the major markets - would produce a net profit of over $73 Billion in the first 10 years.  Such net profit is equal to or greater than the total net profit realized over the last 10 year period by Merck (http://financials.morningstar.com/ratios/r.html?t=MRK) or Gilead (http://financials.morningstar.com/ratios/r.html?t=GILD).  Details of Navigant's analysis are shown on our website at http://www.bioclonetics.com/profit-potential.html.

Moreover, these calculations are based on conservative assumptions - such as assuming a penetration rate (use rate) of the therapy of from 1% in year one to a maximum of 15% in year 5 and assuming a reduction in the population group by the number treated.  

As to the financial potential offered by such therapy, we would direct investors to further information on our website at http://www.bioclonetics.com/profit-potential.html.

From Navigant’s analysis, a present day valuation of our technology was calculated by as being many times that of our currently offered CAP of $10 Million. 

We are excited about our progress and our investor group.  We hope you will join in our goal to provide a real therapy against HIV.